Private equity company THL Partners has announced its agreement to purchase Headlands Research, a multinational clinical trial sites network, from funds managed by investment company KKR.
The transaction is valued at approximately $600m, as per sources who requested anonymity, as reported by Reuters.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The alliance is expected to propel Headlands Research’s ongoing expansion, with a focus on enhancing its centralised infrastructure and technology.
This strategic move is aimed at bolstering Headlands Research’s delivery of trial data to biotech and pharma sponsors, supporting the company’s aim of progressing medical therapies.
Operating across North America, Headlands Research carries out clinical studies in various key therapeutic fields, including vaccines, central nervous system disorders, and metabolic diseases.
The company is said to use physician connections and a data-driven operating model, which broadens trial access to traditionally underrepresented subject groups.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHeadlands was established in 2018 by KKR through its Health Care Strategic Growth Fund to revolutionise the trial site sector and enhance study inclusivity.
The investment in Headlands Research will be made through THL’s Fund IX, with the transaction’s closure anticipated this year, contingent on customary closing conditions.
Advising THL on legal matters for the transaction were McDermott Will & Schulte and Paul, Weiss, Rifkind, Wharton & Garrison, with Jefferies serving as the lead financial advisor.
Edgemont Partners also provided financial advisory services to THL.
KKR and Headlands Research received exclusive financial advice from Houlihan Lokey and legal counsel from Kirkland & Ellis.
Headlands Research CEO Kyle Burtnett said: “I’d like to thank KKR for their tremendous support since our founding. Together, we’ve built an outstanding business with a highly dedicated team working every day to advance medical research.
“THL shares our vision and excitement for the opportunity to accelerate clinical trial innovation, and we couldn’t be more excited to work with their team as we seek to build on the strong foundation that we have in place.”
More than 5,000 clinical studies have so far been completed by Headlands Research.
Last month, Headlands Research acquired Puerto Rico’s clinical research site, CMRCenter, for an undisclosed sum.
